Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

Summary

This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).

Timeline

Start

2023-04-17

Primary completion

2024-03-07

Completion

2024-03-07

Publications

• Background Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR; Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.
• Results Hong JB, Wu PY, Qin A, Huang YW, Tseng KC, Lai CY, Chan WK, Fang J, Cutler DL, Tsai TF. Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics. 2022 Oct 11;14(10):2159. doi: 10.3390/pharmaceutics14102159.

Drugs

Indications